Stoke Therapeutics (STOK)
(Delayed Data from NSDQ)
$16.25 USD
-1.27 (-7.25%)
Updated Jun 14, 2024 04:00 PM ET
After-Market: $16.26 +0.01 (0.06%) 5:42 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
STOK 16.25 -1.27(-7.25%)
Will STOK be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for STOK based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for STOK
Stoke Therapeutics, Inc. (STOK) Reports Q1 Loss, Tops Revenue Estimates
Earnings Preview: Axsome Therapeutics (AXSM) Q1 Earnings Expected to Decline
STOK: What are Zacks experts saying now?
Zacks Private Portfolio Services
Earnings Preview: Stoke Therapeutics, Inc. (STOK) Q1 Earnings Expected to Decline
Stoke Therapeutics (STOK) Up on Upbeat Dravet Syndrome Study Data
Stoke Therapeutics, Inc. (STOK) Reports Q4 Loss, Lags Revenue Estimates
Other News for STOK
Stoke Therapeutics' STK-001: A Potential Game-Changer For Dravet Syndrome
Stoke Therapeutics files to sell 10.84M shares for holders
Stoke Therapeutics files to sell 10.84M shares of common stock for holders
Stoke Therapeutics to Present at Upcoming Investor Conferences in June
Insider Sale: CEO Edward M. Kaye of Stoke Therapeutics Inc (STOK) Sells 42,350 Shares